Endovaginal Medical Ozone Treatment as an Adjuvant in Endometriosis: A Double-Blind Randomized Controlled Trial

Jynani Pichara Morais, Carla Roberta Tim, Cíntia Cristina Santi Martignago, Karina Piva Camargo Volpi, Lívia Assis
In: Ozone: Science & Engineering · 2026 · pp. 1–10 · doi:10.1080/01919512.2026.2644229 · W7138890691
article OA: closed CC0
Full text JSON View on OpenAlex View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

This double-blind randomized controlled trial investigated endovaginal medical ozone treatment as an adjuvant therapy for endometriosis, evaluating its effects.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-07 · read from full text ⓘ

This double-blind, randomized, placebo-controlled trial studied endovaginal medical ozone treatment as an adjuvant therapy for women with endometriosis, enrolling 30 participants assigned to weekly active ozone applications or placebo for 10 weeks. Outcomes were measured at baseline and post-treatment using the Numeric Pain Rating Scale, Endometriosis Health Profile-30, Female Sexual Function Index, and Beck Anxiety Inventory. The ozone group showed significant reductions in pain and improvements in quality of life, sexual function, and anxiety symptoms compared with placebo, with no serious adverse events reported and favorable tolerability. This paper is centrally about endometriosis — it tests endovaginal medical ozone as an adjuvant intervention in a randomized controlled trial and reports pain, quality-of-life, sexual function, and anxiety outcomes.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Full text 1,830 characters · extracted from oa-doi-fallback · click to expand
ABSTRACT Endometriosis is a chronic inflammatory gynecological condition that significantly impacts women’s quality of life. Given the limitations of conventional therapies, complementary strategies are being explored. This randomized, double-blind, placebo-controlled clinical trial evaluated the safety and clinical effects of endovaginal medical ozone treatment as an adjuvant intervention in women with endometriosis. Thirty participants were allocated into placebo (OzP) and active treatment (OzA) groups. Weekly endovaginal applications were performed for 10 weeks. Clinical outcomes were assessed at baseline and post-treatment using the Numeric Pain Rating Scale (NPRS), Endometriosis Health Profile-30 (EHP-30), Female Sexual Function Index (FSFI), and Beck Anxiety Inventory (BAI). The OzA group demonstrated significant reductions in pain and improvements in quality of life, sexual function, and anxiety symptoms compared with OzP. No serious adverse events were observed, and the intervention showed a favorable tolerability profile. These findings suggest that endovaginal medical ozone treatment may represent a minimally invasive adjuvant strategy in endometriosis management. Disclosure statement No potential conflict of interest was reported by the author(s). Data availability statement The datasets generated and analyzed during the current study are not publicly available due to ethical and privacy restrictions involving human participants. Data are available from the corresponding author upon reasonable request and subject to approval by the Institutional Research Ethics Committee. Ethical approval The study was approved by the Human Research Ethics Committee of Universidade Brasil (Plataforma Brasil, protocol 4,506,560) and registered in the Brazilian Clinical Trials Registry (ReBEC, RBR-10fhfdt4)

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Outcome instruments

EHP-30

Condition tags

endometriosis

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (35)

Source provenance

openalex
last seen: 2026-05-14T06:37:26.266404+00:00
License: CC0 · commercial use OK